Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+0.82%
$214.74
100% positive prob.
5-Day Prediction
+3.21%
$219.84
100% positive prob.
20-Day Prediction
+5.77%
$225.29
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q2 2026 | BUY | +0.82% | +3.21% | +5.77% | 100.0% | Pending |
| Q1 2026 | SELL | -1.49% | -2.19% | -0.46% | 100.0% | -4.86% |
| Q4 2025 | BUY | +0.82% | +3.21% | +5.77% | 100.0% | -0.47% |
SEC 8-K filings with transcript text
Jul 23, 2026 · 100% conf.
1D
+0.82%
$214.74
Act: +0.03%
5D
+3.21%
$219.84
20D
+5.77%
$225.29
2 dgx063020268-kex991.htm
Document
Exhibit 99.1
Quest Diagnostics Reports Second Quarter 2026 Financial Results;
Raises Revenue and EPS Guidance for Full Year 2026
•Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth
•Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted diluted EPS of $3.12, up 19.1% from 2025
•Full year 2026 revenues now expected to be between $11.95 billion and $12.05 billion
•Full year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25
SECAUCUS, N.J., July 23, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.
“Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health,” said Jim Davis, Chairman, CEO and President. “Revenues increased by over 10%, almost all from organic revenue growth across our physician, hospital and consumer channels, and adjusted diluted EPS grew over 19%. With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance.”
Recent Highlights:
Serving Customers and Delivering Innovations
•Continued to advance our Co-Lab Solutions implementation and joint venture laboratory with Corewell Health in Michigan and developed new capabilities in kidney care through our collaboration with Fresenius Medical Care in the United States.
•Generated robust revenue growth through questhealth.com and our consumer, wearable and wellness partners.
•Grew revenues by double-digits in several areas of Advanced Diagnostics, including Quest AD-Detect® blood tests for Alzheimer’s disease and advanced cardiometabolic and endocrine tests, including liver fibrosis testing.
•Granted New York State approval for our Haystack MRD® test and became the largest reference lab to utilize Flatiron Health's OncoEMR® Molecular Profiling Integration (MPI) platform for select cancer tests, including Haystack MRD, starting with a pilot with American Oncology Network (AON).
Driving Operational Excellence
•In the lab, extended automation solutions to improve quality and productivity in cervical cancer screening and front-end specimen processing to additional labs.
•Outside the lab, launched IntelliDraw™ to guide clinical staff of our physician customers through specimen collection, to enhance quality and the service experience.
1
Three Months Ended June 30,Six Months Ended June 30,
20262025Change20262025Change
(dollars in millions, except per share data)
Reported:
Net revenues$3,043 $2,761 10.2 %$5,938 $5,413 9.7 %
Diagnostic Information Services revenues$2,978 $2,699 10.3 %$5,810 $5,288 9.9 %
Revenue per requisition(2.8)%(2.1)%
Requisition volume13.1 %12.0 %
Organic requisition volume13.0 %11.9 %
Operating income (a)$459 $438 4.6 %$858 $784 9.4 %
Operating income as a percentage of net revenues (a)15.1 %15.9 %(0.8)%14.4 %14.5 %(0.1)%
Net income attributable to Quest Diagnostics (a)$320 $282 13.4 %$572 $502 13.9 %
Diluted EPS (a)$2.84 $2.47 15.0 %$5.08 $4.41 15.2 %
Cash provided by operations $597 $544 9.7 %$875 $858 1.9 %
Capital expenditures$138 $108 27.0 %$252 $225 12.1 %
Adjusted (a):
Operating income$502 $466 7.8 %$949 $872 8.8 %
Operating income as a percentage of net revenues16.5 %16.9 %(0.4)%16.0 %16.1 %(0.1)%
Net income attributable to Quest Diagnostics$350 $298 17.3 %$631 $549 14.9 %
Diluted EPS$3.12 $2.62 19.1 %$5.62 $4.83 16.4 %
(a)For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.
Updated Guidance for Full Year 2026
The company updates its full year 2026 guidance as follows:
Updated GuidancePrior Guidance
LowHighLowHigh
Net revenues$11.95 billion$12.05 billion$11.78 billion$11.90 billion
Net revenues increase8.3%9.2%6.8%7.8%
Reported diluted EPS$9.97$10.17$9.58$9.78
Adjusted diluted EPS$11.05$11.25$10.63$10.83
Cash provided by operationsApproximately $1.80 billionApproximately $1.75 billion
Capital expenditures Approximately $550 millionApproximately $550 million
Based on the favorable resolution of various tax contingencies in the second quarter, the full year adjusted effective tax rate is expected to be consistent with 2025.
Note on Non-GAAP Financial Measures
As used in this press release the term “reported” refers to measures under accounting principles generally accepted in the United States (“GAAP”). The term “adjusted” refers to non-GAAP operating performance measures that exclude special items such as res
Apr 21, 2026 · 100% conf.
1D
-1.49%
$201.98
Act: -0.51%
5D
-2.19%
$200.54
Act: -4.86%
20D
-0.46%
$204.11
Act: -7.14%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.ce06d217.1784386256.ac52fb37
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Feb 10, 2026 · 100% conf.
1D
+0.82%
$207.03
Act: +1.93%
5D
+3.21%
$211.95
Act: -0.47%
20D
+5.77%
$217.20
dgx-202602100001022079false00010220792026-02-102026-02-10
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): February 10, 2026
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 10, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 8.01. Other Events
On February 10, 2026, the Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $1 billion of the Company's common stock as part of the Company's common stock repurchase program and increased the quarterly dividend from $0.80 to $0.86 per share. The 7.5% increase in the quarterly dividend is effective with the dividend payable on April 20, 2026 to shareholders of record of the Company’s common stock on April 6, 2026. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated February 10, 2026 announcing, among other things, its results for the quarter and full year ended December 31, 2025.
99.2Press release of Quest Diagnostics Incorporated dated February 10, 2026, announcing the increase in its quarterly dividend and the increase in its share repurchase authorization.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
February 10, 2026
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Jan 12, 2026 · 100% conf.
1D
+0.82%
$207.03
Act: +1.93%
5D
+3.21%
$211.95
Act: -0.47%
20D
+5.77%
$217.20
false 0001022079
0001022079
2026-01-12 2026-01-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): January 12, 2026
Quest Diagnostics Incorporated
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or other jurisdiction of incorporation)
001-12215
16-1387862
(Commission File Number)
(I.R.S. Employer Identification No.)
500 Plaza Drive
Secaucus, NJ
07094
(Address of principal executive offices)
(Zip Code)
(973) 520-2700
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 Par Value DGX New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
To the extent applicable, the information furnished under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is incorporated into this Item 2.02 by reference.
Item 7.01. Regulation FD Disclosure
On January 12, 2026, Quest Diagnostics Incorporated (the “Company”) will speak on the Company's strategy, performance, and the latest market developments and trends during a
A copy of the presentation materials to be used by the Company at the Conference are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated into this Item 7.01 of this Current Report on Form 8-K by reference. The presentation materials include information regarding the matters discussed by the Company at the Conference.
The information in the preceding paragraphs, as well as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references this Current Report on Form 8-K.
The statements in the presentation materials which are not historical facts may be forward-looking statements. Readers and others are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers, or strategic partners, acquisitions, and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1
104 The cover page from this cur
Oct 21, 2025
dgx-202510210001022079false00010220792025-10-212025-10-21
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): October 21, 2025
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On October 21, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated October 21, 2025 announcing, among other things, its results for the quarter ended September 30, 2025.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
October 21, 2025
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Jul 22, 2025
dgx-202507220001022079false00010220792025-07-222025-07-22
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): July 22, 2025
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On July 22, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated July 22, 2025, announcing, among other things, its results for the quarter ended June 30, 2025.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
July 22, 2025
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Apr 22, 2025
dgx-202504220001022079false00010220792025-04-222025-04-22
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): April 22, 2025
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On April 22, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated April 22, 2025, announcing, among other things, its results for the quarter ended March 31, 2025.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
April 22, 2025
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Jan 30, 2025
dgx-202501300001022079false00010220792025-01-302025-01-30
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): January 30, 2025
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus,NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On January 30, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 8.01. Other Events
On January 30, 2025, the Company announced that its Board of Directors had authorized a 6.7% increase in its quarterly dividend from $0.75 to $0.80 per share, or $3.20 per share annually, effective with the dividend payable on April 21, 2025 to shareholders of record of Quest Diagnostics Incorporated common stock on April 7, 2025. The Company has raised its dividend annually since 2011. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated January 30, 2025, announcing, among other things, its results for the quarter and full year ended December 31, 2024.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
January 30, 2025
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Oct 22, 2024
dgx-202410220001022079false00010220792024-10-222024-10-22
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): October 22, 2024
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On October 22, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated October 22, 2024, announcing, among other things, its results for the quarter ended September 30, 2024.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
October 22, 2024
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Jul 23, 2024
dgx-202407230001022079false00010220792024-07-232024-07-23
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): July 23, 2024
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On July 23, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated July 23, 2024, announcing, among other things, its results for the quarter ended June 30, 2024.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
July 23, 2024
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Apr 23, 2024
dgx-202404230001022079false00010220792024-04-232024-04-23
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): April 23, 2024
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On April 23, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated April 23, 2024, announcing, among other things, its results for the quarter ended March 31, 2024.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
April 23, 2024
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Feb 1, 2024
dgx-202402010001022079false00010220792024-02-012024-02-01
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): February 1, 2024
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus,NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 1, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 8.01. Other Events
On February 1, 2024, the Company announced that its Board of Directors had authorized a 5.6% increase in its quarterly dividend from $0.71 to $0.75 per share, or $3.00 per share annually, effective with the dividend payable on April 22, 2024 to shareholders of record of Quest Diagnostics Incorporated common stock on April 8, 2024. The Company has raised its dividend annually since 2011. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated February 1, 2024, announcing, among other things, its results for the quarter and full year ended December 31, 2023.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
February 1, 2024
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Oct 24, 2023
dgx-202310240001022079false00010220792023-10-242023-10-24
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): October 24, 2023
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On October 24, 2023, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated October 24, 2023, announcing, among other things, its results for the quarter ended September 30, 2023.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
October 24, 2023
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Jul 26, 2023
dgx-202307260001022079false00010220792023-07-262023-07-26
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): July 26, 2023
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On July 26, 2023, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated July 26, 2023, announcing, among other things, its results for the quarter ended June 30, 2023.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
July 26, 2023
By:/s/ Sean D. Mersten Sean D. Mersten Vice President and Corporate Secretary
Apr 27, 2023
dgx-202304270001022079false00010220792023-04-272023-04-27
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): April 27, 2023
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On April 27, 2023, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 7.01. Regulation FD Disclosure
On April 27, 2023, the Company issued a press release announcing it entered into a definitive agreement to acquire Haystack Oncology, Inc., an early-stage oncology company focused on minimal residual disease (MRD) testing. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated April 27, 2023, announcing, among other things, its results for the quarter ended March 31, 2023.
99.2Press release of Quest Diagnostics Incorporated dated April 27, 2023, announcing it entered into a definitive agreement to acquire Haystack Oncology, Inc.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
April 27, 2023
By:/s/ William J. O'Shaughnessy, Jr. William J. O'Shaughnessy, Jr. Deputy General Counsel and Corporate Secretary
Feb 2, 2023
dgx-202302020001022079false00010220792023-02-022023-02-02
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): February 2, 2023
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus,NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 2, 2023, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 8.01. Other Events
On February 2, 2023, the Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $1 billion of the Company's common stock as part of the Company's common stock repurchase program and increased the quarterly dividend from $0.66 to $0.71 per share. The 7.6% increase in the quarterly dividend is the Company’s twelfth since 2011 and is effective with the dividend payable on April 24, 2023 to shareholders of record of the Company’s common stock on April 10, 2023. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated February 2, 2023, announcing, among other things, its results for the quarter and full year ended December 31, 2022.
99.2Press release of Quest Diagnostics Incorporated dated February 2, 2023, announcing the increase in its quarterly dividend and the increase in its share repurchase authorization.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
February 2, 2023
By:/s/ William J. O'Shaughnessy, Jr. William J. O'Shaughnessy, Jr. Deputy General Counsel and Corporate Secretary
Oct 20, 2022
dgx-202210200001022079false00010220792022-10-202022-10-20
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): October 20, 2022
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On October 20, 2022 Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated October 20, 2022, announcing, among other things, its results for the quarter ended September 30, 2022.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
October 20, 2022
By:/s/ William J. O'Shaughnessy, Jr. William J. O'Shaughnessy, Jr. Deputy General Counsel and Corporate Secretary
Jul 21, 2022
dgx-202207210001022079false00010220792022-07-212022-07-21
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): July 21, 2022
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On July 21, 2022 Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated July 21, 2022, announcing, among other things, its results for the quarter ended June 30, 2022.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
July 21, 2022
By:/s/ William J. O'Shaughnessy, Jr. William J. O'Shaughnessy, Jr. Deputy General Counsel and Corporate Secretary
Apr 21, 2022
dgx-202204210001022079false00010220792022-04-212022-04-21
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): April 21, 2022
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On April 21, 2022 Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated April 21, 2022, announcing, among other things, its results for the quarter ended March 31, 2022.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
April 21, 2022
By:/s/ William J. O'Shaughnessy, Jr. William J. O'Shaughnessy, Jr. Deputy General Counsel and Corporate Secretary
Feb 3, 2022
dgx-202202030001022079false00010220792022-02-032022-02-03
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of Earliest Event Reported): February 3, 2022
Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or other jurisdiction of incorporation)
001-1221516-1387862 (Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus,NJ07094 (Address of principal executive offices)(Zip Code)
(973)520-2700 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 3, 2022 Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 8.01. Other Events
On February 3, 2022, the Company announced that its Board of Directors increased its quarterly dividend from $0.62 to $0.66 per share. The 6.5% increase in the quarterly dividend is the Company’s eleventh since 2011 and is effective with the dividend payable on April 20, 2022 to shareholders of record of the Company’s common stock on April 6, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1Press release of Quest Diagnostics Incorporated dated February 3, 2022, announcing, among other things, its results for the quarter and full year ended December 31, 2021.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
February 3, 2022
By:/s/ William J. O'Shaughnessy, Jr. William J. O'Shaughnessy, Jr. Deputy General Counsel and Corporate Secretary
This page provides Quest Diagnostics Incorporated (DGX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on DGX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.